Enhancing the landscape of colorectal cancer using targeted deep sequencing
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Targeted next-generation sequencing (NGS) technology detects specific mutations that can provide treatment opportunities for colorectal cancer (CRC) patients. We included 145 CRC patients who underwent surgery. We analyzed the mutation frequencies of common actionable genes and their association with clinicopathological characteristics and oncologic outcomes using targeted NGS. Approximately 97.9% (142) of patients showed somatic mutations. Frequent mutations were observed in TP53 (70%), APC (60%), and KRAS (49%). TP53 mutations were significantly linked to higher overall stage (p = 0.038) and lower disease-free survival (DFS) (p = 0.039). ATM mutation was significantly associated with higher tumor stage (p = 0.012) and shorter overall survival (OS) (p = 0.041). Stage 3 and 4 patients with ATM mutations (p = 0.023) had shorter OS, and FBXW7 mutation was significantly associated with shorter DFS (p = 0.002). However, the OS of patients with or without TP53, RAS, APC, PIK3CA, and SMAD4 mutations did not differ significantly (p = 0.59, 0.72, 0.059, 0.25, and 0.12, respectively). Similarly, the DFS between patients with RAS, APC, PIK3CA, and SMAD4 mutations and those with wild-type were not statistically different (p = 0.3, 0.79, 0.13, and 0.59, respectively). In multivariate Cox regression analysis, ATM mutation was an independent biomarker for poor prognosis of OS (p = 0.043). A comprehensive analysis of the molecular markers for CRC can provide insights into the mechanisms underlying disease progression and help optimize a personalized therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TP53 and PIK3CA are commonly mutated in colorectal cancer and have been postulated to potentially affect treatment response and sensitivity to KRAS inhibition.35,36”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Maftools: efficient and comprehensive analysis of somatic variants in cancer
Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C., & Koeffler, H. P. (2018) · Genome Research · doi:10.1101/gr.239244.118 · Cited by 4,935
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Landon, M., Saam, J., Brown, K. L., Moyes, K., Evans, B., & Wenstrup, R. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,939
Variant Review with the Integrative Genomics Viewer
Robinson, J. T., Thorvaldsdóttir, H., Wenger, A. M., Zehir, A., & Mesirov, J. P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0337 · Cited by 1,115
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,041
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas
Liu, Y., Sethi, N. S., Hinoue, T., Schneider, B. G., Cherniack, A. D., Sanchez-Vega, F., Seoane, J. A., Farshidfar, F., Bowlby, R., Islam, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.010 · Cited by 615
Histopathological Identification of Colon Cancer with Microsatellite Instability
Alexander, J., Watanabe, T., Wu, T.-T., Rashid, A., Li, S., & Hamilton, S. R. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63994-6 · Cited by 511
The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479
Signaling pathways involved in colorectal cancer progression
Koveitypour, Z., Panahi, F., Vakilian, M., Peymani, M., Seyed Forootan, F., Nasr Esfahani, M. H., & Ghaedi, K. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0361-4 · Cited by 393
Mitry, E., Guiu, B., Cosconea, S., Jooste, V., Faivre, J., & Bouvier, A.-M. (2010) · Gut · doi:10.1136/gut.2010.211557 · Cited by 377
Clinical and molecular characterization of early‐onset colorectal cancer
Willauer, A. N., Liu, Y., Pereira, A. A. L., Lam, M., Morris, J. S., Raghav, K. P. S., Morris, V. K., Menter, D., Broaddus, R., Meric‐Bernstam, F., et al. (2019) · Cancer · doi:10.1002/cncr.31994 · Cited by 375
SMAD2,SMAD3 and SMAD4 Mutations in Colorectal Cancer
Fleming, N. I., Jorissen, R. N., Mouradov, D., Christie, M., Sakthianandeswaren, A., Palmieri, M., Day, F., Li, S., Tsui, C., Lipton, L., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2706 · Cited by 324
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
Nakayama, M., & Oshima, M. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy075 · Cited by 282
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Taieb, J., Le Malicot, K., Shi, Q., Penault Lorca, F., Bouché, O., Tabernero, J., Mini, E., Goldberg, R. M., Folprecht, G., Luc Van Laethem, J., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw272 · Cited by 273
Poynter, J. N., Siegmund, K. D., Weisenberger, D. J., Long, T. I., Thibodeau, S. N., Lindor, N., Young, J., Jenkins, M. A., Hopper, J. L., Baron, J. A., et al. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0512 · Cited by 229
Sporadic colorectal adenocarcinomas with high‐frequency microsatellite instability
Gafà, R., Maestri, I., Matteuzzi, M., Santini, A., Ferretti, S., Cavazzini, L., & Lanza, G. (2000) · Cancer · doi:10.1002/1097-0142(20001115)89:10<2025::aid-cncr1>3.3.co;2-j · Cited by 216
A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms11743 · Cited by 207
Heinemann, V., Stintzing, S., Kirchner, T., Boeck, S., & Jung, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.005 · Cited by 203
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin, H.-T., Choi, Y.-L., Yun, J. W., Kim, N. K. D., Kim, S.-Y., Jeon, H. J., Nam, J.-Y., Lee, C., Ryu, D., Kim, S. C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01470-y · Cited by 203
Self-citationSepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Lieu, C., Lindor, N. M., Minsky, B. D., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0554-cp · Cited by 172
FBXW7 in Cancer: What Has Been Unraveled Thus Far?
Sailo, B. L., Banik, K., Girisa, S., Bordoloi, D., Fan, L., Halim, C. E., Wang, H., Kumar, A. P., Zheng, D., Mao, X., et al. (2019) · Cancers · doi:10.3390/cancers11020246 · Cited by 166
Detection of Microsatellite Instability by Fluorescence Multiplex Polymerase Chain Reaction
Berg, K. D., Glaser, C. L., Thompson, R. E., Hamilton, S. R., Griffin, C. A., & Eshleman, J. R. (2000) · The Journal of Molecular Diagnostics · doi:10.1016/s1525-1578(10)60611-3 · Cited by 163
Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study.
Dinu, D., Dobre, M., Panaitescu, E., Bîrlă, R., Iosif, C., Hoara, P. A., Caragui, A., Boeriu, M., Constantinoiu, S. M., & Ardeleanu, C. M. (2014) · PubMed Central · Cited by 153
Aghabozorgi, A. S., Bahreyni, A., Soleimani, A., Bahrami, A., Khazaei, M., Ferns, G. A., Avan, A., & Hassanian, S. M. (2019) · Biochimie · doi:10.1016/j.biochi.2018.11.003 · Cited by 144
Toon, C. W., Walsh, M. D., Chou, A., Capper, D., Clarkson, A., Sioson, L., Clarke, S., Mead, S., Walters, R. J., Clendenning, M., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31828f233d · Cited by 136
Prediction of Cancer Incidence and Mortality in Korea, 2019
Jung, K., Won, Y., Kong, H., & Lee, E. S. (2019) · Cancer Research and Treatment · doi:10.4143/crt.2019.139 · Cited by 129
ATM: Expanding roles as a chief guardian of genome stability
Shiloh, Y. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.09.002 · Cited by 118
ASBL, O. B. O. I. P., Deans, Z. C., Costa, J. L., Cree, I. A., Dequeker, E., Edsjö, A., Henderson, S. J., Hummel, M., Ligtenberg, M. J. L., Loddo, M., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2025-7 · Cited by 118
Al-Shamsi, H. O., Jones, J. C., Fahmawi, Y., Dahbour, I., Tabash, A., Abdel‐Wahab, R., Abousamra, A., Shaw, K. R. M., Xiao, L., Hassan, M. M., et al. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.11.02 · Cited by 94
Sarshekeh, A. M., Advani, S., Overman, M. J., Manyam, G., Kee, B. K., Fogelman, D. R., Dasari, A., Raghav, K., Vilar, E., Manuel, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0173345 · Cited by 84
FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma
Korphaisarn, K., Morris, V. K., Overman, M. J., Fogelman, D. R., Kee, B. K., Raghav, K. P. S., Manuel, S., Shureiqi, I., Wolff, R. A., Eng, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16848 · Cited by 74
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
Randon, G., Fucà, G., Rossini, D., Raimondi, A., Pagani, F., Perrone, F., Tamborini, E., Busico, A., Peverelli, G., Morano, F., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39525-3 · Cited by 70
Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability
Umeda, Y., Nagasaka, T., Mori, Y., Sadamori, H., Sun, D., Shinoura, S., Yoshida, R., Satoh, D., Nobuoka, D., Utsumi, M., et al. (2012) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-012-0531-9 · Cited by 66
Beggs, A. D., Domingo, E., McGregor, M. J., Presz, M., Johnstone, E. C., Midgley, R. S., Kerr, D. J., Oukrif, D., Novelli, M. R., Abulafi, M., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.694 · Cited by 63
Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP
Valentino, E., Bellazzo, A., Minin, G. D., Sicari, D., Apollonio, M., Scognamiglio, G., Bonito, M. D., Botti, G., Sal, G. D., & Collavin, L. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700996114 · Cited by 61
Mutation spectra of RAS gene family in colorectal cancer
Chang, Y.-Y., Lin, P.-C., Lin, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Liang, W.-Y., & Chang, S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.02.013 · Cited by 60
Dallol, A., Buhmeida, A. S., Al-Ahwal, M. S., Al-Maghrabi, J. A., Bajouh, O. S., Alkhayyat, S. S., Alam, R., Abusanad, A. M., Turki, R. F., Elaimi, A., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0878-9 · Cited by 42
Screening Patients With Colorectal Cancer for Lynch Syndrome: What Are We Waiting For?
Kastrinos, F., & Syngal, S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7171 · Cited by 40
Lack ofAPCsomatic mutation is associated with early-onset colorectal cancer in African Americans
Xicola, R. M., Manojlovic, Z., Augustus, G. J., Kupfer, S. S., Emmadi, R., Alagiozian-Angelova, V. M., Triche, T. J., Salhia, B., Carpten, J. D., Llor, X., et al. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy122 · Cited by 40
Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
Hu, J. Y., Yan, W., Xie, L., Cheng, L., Yang, M., Li, L., Shi, J., Liu, B., & Qian, X. (2016) · Medicine · doi:10.1097/md.0000000000005649 · Cited by 35
Elsaleh, H., Shannon, B. A., & Iacopetta, B. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.23646 · Cited by 33
Lee, A., Lee, S. H., Jung, C. K., Park, G., Lee, K. Y., Choi, H. J., Min, K. O., Kim, T. J., Lee, E. J., & Lee, Y. S. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.03.009 · Cited by 30
Self-citationNon‐V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
Osumi, H., Shinozaki, E., Wakatsuki, T., Suenaga, M., Ichimura, T., Ogura, M., Takahari, D., Ooki, A., Suzuki, T., Ota, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32320 · Cited by 25
Chang, Y., Lee, C., Ke, T., Chang, C., Chao, D., Huang, H., & Chang, J. (2019) · Cancer Medicine · doi:10.1002/cam4.2282 · Cited by 25
Self-citationFbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models
Grim, J. E. (2013) · Gut · doi:10.1136/gutjnl-2013-305144 · Cited by 16
Koyel, B., Das, P., Bhattacharya, R. K., Swati, D., Mukhopadhyay, S., Basak, J., & Ashis, M. (2017) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-017-0651-4 · Cited by 10
Cited by
Next-Generation Sequencing Technology: Current Trends and Advancements
Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R. P., Banday, S., Mishra, A. K., Das, G., et al. (2023) · Biology · doi:10.3390/biology12070997 · Cited by 1,299
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers
Jiang, J., Jiang, L., Maldonato, B. J., Wang, Y., Holderfield, M., Aronchik, I., Winters, I. P., Salman, Z., Blaj, C., Menard, M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0027 · Cited by 343
Clinical significance of FBXW7 loss of function in human cancers
Fan, J., Bellon, M., Ju, M., Zhao, L., Wei, M., Fu, L., & Nicot, C. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01548-2 · Cited by 169
The DNA Damage Response and Inflammation in Cancer
Klapp, V., Álvarez-Abril, B., Leuzzi, G., Kroemer, G., Ciccia, A., & Galluzzi, L. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1220 · Cited by 123
Metadata
- Authors
- Lee, C. S., Song, I. H., Lee, A., Kang, J., Lee, Y. S., Lee, I. K., Song, Y. S., & Lee, S. H.
- Affiliations
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Konyang University (KR)
- Corresponding author
- Song, Young Soo
- Lee, Sung Hak
- ORCID
- Venue
- Scientific Reports
- Published
- 2021-04-14
- Volume
- 11
- Issue
- 1
- Pages
- 8154-8154
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC8046812
- OpenAlex
- W3155663898
- Cited by
- 64
- References
- 52
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 12 · 2023: 14 · 2022: 14 · 2021: 3
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation
- National Research Foundation of Korea (2019R1F1A1062367)
- Ministry of Science and ICT, South Korea
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, somatic mutations, actionable genes, TP53, APC, KRAS, ATM, FBXW7, PIK3CA, SMAD4, prognostic factors, disease-free survival, overall survival, tumor stage, targeted deep sequencing
- MeSH terms
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, Survival Analysis, Sequence Analysis, DNA, High-Throughput Nucleotide Sequencing, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.